Despite the remarkable success of PD1/PDL1 inhibitors in treating certain cancers like melanoma and non-small-cell lung cancer [18,19,20], a significant proportion of patients fail to achieve long-term and sustained efficacy from this therapy [21,22,23]. Here, PDCD1 is linked to cancer.